A case study of a young patient with sickle cell disease who was successfully treated with an experimental gene therapy has been published in the 2 March 2017 edition of The New England Journal of Medicine. It is believed to be the first treatment to deliver substantial relief from a disease that can sometimes lead to an early death.
TxCell SA expects to start a clinical trial in late 2018 of a regulatory T cell product that has been engineered to contain a chimeric antigen receptor (CAR). The French company’s therapeutic focus is severe inflammatory and autoimmune diseases as well as organ transplant rejection.
Innate Pharma SA continued its strategy for attacking cancer by mobilizing cells in the innate immune system in 2016. Under an agreement with Bristol-Myers Squibb, the France-based company received a milestone payment of $15 million following progress in the development of lirilumab.
MorphoSys is poised to reap the rewards of a decade-long strategy as a technology provider with the regulatory filing by it partner Janssen for the approval of guselkumab, an antibody treatment for plaque psoriasis.
One of the biggest European Series A financings so far this year has been arranged by venture capitalists for a new company with technology to treat patients with lung transplants who are at risk of dying because of a condition known as bronchiolitis obliterans syndrome (BOS).
Novo Nordisk A/S, the global producer of diabetes products, has put Doug Langa in charge of its US operations following the resignation of Jakob Riis. Mr Riis will move to Falck A/S, an emergency services company, as president and chief executive officer, on 1 May.
A research collaboration dating from 2015 has yielded a licensing agreement for Argenx NV of Belgium. The deal involves an antibody targeted ApoC3, a protein involved in dyslipidemia, a disorder caused by an abnormal amount of lipids in the blood.
Denmark-based ALK-Abelló A/S is preparing for an expansion of its business in the US following the Food and Drug Administration’s approval on 1 March of its allergy immunotherapy tablet Odactra for adults with house dust mite allergies.
Ipsen SA, the French specialty pharma company, reported substantial increases in revenue and operating profit for 2016. It expects the momentum to continue in 2017 when its $1 billion acquisition of Onivyde (irinotecan liposome) for treating metastatic pancreatic cancer should be completed.
Nordic Nanovector ASA has its sights on expanding the application of its experimental radioimmunotherapies in haematological cancers following positive early data for its lead product Betalutin in follicular lymphoma. Betalutin is an antibody conjugated to a radionuclide.